Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decrease in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 42,300 shares, a decline of 23.8% from the February 13th total of 55,500 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average daily volume of 63,400 shares, the short-interest ratio is presently 0.7 days.

Lixte Biotechnology Stock Performance

Shares of NASDAQ LIXT traded up $0.02 during trading on Monday, hitting $1.23. The company had a trading volume of 7,139 shares, compared to its average volume of 317,640. The company has a market cap of $2.77 million, a P/E ratio of -0.71 and a beta of 0.19. Lixte Biotechnology has a 52 week low of $1.02 and a 52 week high of $4.40. The business’s 50-day moving average is $1.92 and its 200 day moving average is $1.91.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC purchased a new stake in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned approximately 0.56% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 5.10% of the company’s stock.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.